Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

No one here cares about the vigabartrin (which Nasrat sold and will only manufacture for a few years because it didn't fit into our drug portfolio) or the Mikah generics. None of these drugs are relevant at all to the company now or its future price. More importantly none of them was capable of transforming the company like the CNS products are doing right now.

I agree about the Mikah generics. They were never going to take this company anywhere. $10 million was a massive overcharge. The deal was arranged and approved by the Elite board of directors, a majority of whom were business partners with Hakim via Epic Investments. You should ask if we can have our 300+ million shares back. As for manufacturing vigabatrin for a few years, I think you misunderstand the nature of that transaction. The buyer has a new version of vigabatrin they are promoting, and they are not interested in having themselves as a generic competitor. There will be no orders for generic vigabatrin. Whatever profit was recorded from the sale of the ANDA is all there will be.

Do the math. We have PE in the low 20s without any of the revenue from the approved Methotrexate or the opiods (combined market total over $ 1 billion). Those together will bring in at least $50 million more a year in revenue (assuming a conservative 5% market penetration). That more than justifies the current $0.40 today. Throw in Vyvanse which has a successful BE and no big questions from the FDA. Plus more billion dollar products under development, plus a CEO who says he is growing the company with the goal of M&A in a couple of years.

Again, I'm very happy to agree with you on all of this, but you and everyone reading this knows that none of it is why the price went from .19 to .39. That movement was all about Vyvanse being approved this year, and if it doesn't happen, then the share price will reflect it. It's okay to be hopeful, but it's not helpful to be delusional about the acute risks involved in penny stock investing. Who says there are no big questions about Vyvanse from the FDA? Let me tell you, it is the same guy who said SequestOx was a labeling issue. Once bitten, twice shy. I hope it's true, but I'm not counting on it. I still believe ELTP can be a transformational stock, otherwise I wouldn't have held my position for so long. And I still believe Vyvanse will ultimately get an FDA approval, but I also know there are a million uncontrollable reasons why that might not happen this year. If there is a CRL in November, the next PDUFA date could be well into 2025. I doubt you or anyone seriously believes we wouldn't take a big hit in that scenario. Be real.

.